Catena Biosciences is a UC Berkeley-spun next-generation ADC platform whose proprietary cysteine-tyrosine (C-Y) Bond lets a single antibody carry multiple distinct payloads, a structural wedge over the single-payload linker chemistries behind the recent billion-dollar ADC exits. Built on technology from the Francis and Doudna labs, the CysTyr platform uses an engineered Catenase enzyme to couple biomolecules through native amino acids, producing Multi-Payload Conjugates (MPC) that attach payloads of differing size and mechanism to one antibody with a bond the company claims is considerably more stable than conventional maleimide chemistry. The company is developing dual-payload ADCs for solid tumors, with its lead asset in non-human-primate studies after a multi-gram CDMO scale-up.
The validation is in the syndicate, not yet in the clinic. As of the 2026-07-15 note, Arch Venture Partners is "nearly committed" and targeting a roughly $110M total allocation with likely tranching, while 5AM Ventures, Foresight, and 8VC are all in the data room and a $2M SBIR grant has been confirmed and awarded. Earlier, per the 2026-05-22 dinner readout relayed by Miles Bird, Marco framed an initial tranche pricing near a $30M–$40M pre-money and floated whether StoryHouse should raise its hand for a $1M–$2M check from Fund II, potentially alongside ProRata to enlarge the allocation. This is a preclinical, platform-stage bet: the upside is a red-hot bioconjugation M&A tape; the tension is undefined terms and a company cutting salaries to conserve cash into September.
Antibody-drug conjugates are one of oncology's fastest-growing modalities: market estimates cluster around $15B in 2025 and forecast roughly $33B by 2035 at a single-digit-to-low-double-digit CAGR (methodologies range from ~9% to ~12%) Web. Timing favors platforms that improve payload flexibility and linker stability: big pharma is paying up for next-generation conjugation technology, and Catena's multi-payload approach targets exactly the limitation, single-payload and largely small-molecule-restricted designs, that current ADCs face Web.
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| Catena Biosciences | CysTyr / C-Y Bond, dual-payload Multi-Payload Conjugates (MPC) for solid tumors | Series A (raising); preclinical, lead in NHP studies | — |
| Araris Biotech | AraLinQ one-step site-specific enzymatic linker on off-the-shelf antibodies | Acquired by Taiho: $400M upfront, up to $1.14B (Mar 2025) | Catena's C-Y Bond loads multiple distinct payloads per antibody vs. a single-payload linker |
| Synaffix | GlycoConnect / HydraSpace glycan-based site-specific ADC platform | Acquired by Lonza: €100M upfront + up to €60M (Jun 2023) | Multi-payload flexibility and native-amino-acid chemistry as the differentiator |
| Tubulis | Next-gen ADC platform plus a clinical asset (TUB-040) for solid tumors | Acquired by Gilead: $3.15B upfront, up to $5B (2026) | Catena earlier-stage; competes on platform breadth, not a clinical asset |
Moat: a proprietary cysteine-tyrosine (C-Y) Bond formed by an engineered Catenase enzyme, developed in the Francis and Doudna labs at UC Berkeley, that couples proteins through native amino acids to load multiple payloads with claimed stability advantages over maleimide chemistry Web.
The bioconjugation / ADC M&A tape is exceptionally strong: Gilead acquired Tubulis for $3.15B upfront (up to $5B) in 2026 Web, Taiho acquired ADC-linker peer Araris for $400M upfront (up to $1.14B) in 2025 Web, and Lonza acquired Synaffix in 2023 for €100M upfront plus up to €60M Web. Likely acquirers are large-cap oncology players building ADC platforms (Gilead, Taiho) and ADC-focused CDMOs (Lonza), plus the majors. Against an initial ~$30M–$40M pre-money entry (2026-05-22 note), platform M&A comps in the $1B+ range imply a high potential multiple, gated by the binary risk of a preclinical, platform-stage asset. Internal
Per public sources, the founding / leadership team also includes co-founders Matthew Francis (UC Berkeley professor) and Geo Guillen, and CSO Rick Kendall.
Marco update: Arch is nearly committed and targeting a ~$110M total allocation with tranching, competing term sheets are being cultivated for leverage, and the team is cutting salaries to reach a September close.
CatenaBio company update. Arch Capital has nearly committed to investing, targeting $110M total allocation with likely tranching. Arch wants Ron Phillip (current advisor) to take an operational role, likely CEO; Marco views Ron positively and sees this as a good outcome. GP Christina Bro requested a brief on non-oncology expansion programs before IC; Marco delivered that brief over the weekend and expects Arch to wrap its process within a week.
Running low on funds, so capital-conservation measures are in place; the executive team is taking salary cuts to extend runway to September. A $2M SBIR grant is confirmed and awarded, awaiting drawdown (expected by August, possibly September). Civilization Ventures offered to top up the bridge SAFE if needed to cover any gap; Cal Innovation Fund has as well; Matthew and Josh offered as well.
Competing term sheets are being pursued to strengthen negotiating leverage. 5AM Ventures re-engaged, with its next IC July 27/28, and it is in the data room doing diligence. Foresight is also in the data room. 8VC (Francisco) is in the data room but moving slowly. Cal Innovation Fund (Berkeley-affiliated) meets tomorrow, with likely ~$200K available to deploy if needed.
Arch has alluded to a potential merger with an existing shell company, which Marco thinks is a bit odd and is unsure of; no confirmed structure or assets disclosed.
Relayed by Miles Bird via email from a dinner with Marco: the round is not closed, but Arch has moved quickly on life-sciences diligence, and StoryHouse needs to decide whether to raise its hand for a $1M–$2M Fund II check.
Good update from Marco during dinner, relayed by Miles Bird via email. While the deal is not yet closed, Marco feels more confident because one of his advisors, Ron, is giving him an inside perspective on the process, as Ron is in all the IC meetings with Arch.
Marco said Catena originally received an offer from a top life-sciences firm (name not recalled). Arch Venture Partners has since moved quickly to complete life-sciences diligence, currently underway. Marco believes both Arch and the other major life-sciences firm may each want to invest ~$35M and co-lead. Shahram has indicated interest in potentially investing $20M in this round, and other insiders may also participate. Marco expects the initial tranche to price at roughly $30M–$40M pre-money.
The question for StoryHouse: should we raise our hand for a $1M–$2M check from Fund II, and communicate interest to Marco soon? If we want to partner with ProRata or another group to increase our allocation, we should indicate that soon as well.
Marco update covering a possible Doudna/StoryHouse event and the Series A: the team is pushing Arch to move, and momentum is picking back up after correcting other VCs' confusion on human tolerance.
Jennifer Doudna / event with StoryHouse + Baker Labs: Marco said Doudna's engagement with the company has been lower recently, largely because their current work isn't directly focused on the CRISPR side of the field. He's had mixed success getting her involved in external events. However, she's increasingly interested in entrepreneurship and founder support, particularly through IGI-related companies and companies where she is a co-founder. Best next step: draft a concise event proposal featuring companies where Jennifer is involved, with StoryHouse inviting its investor network, and Marco to send it to Jennifer with the StoryHouse team cc'ed.
Series A fundraising update: Ron and John are pushing hard internally on the round. Newpath has been highly engaged and actively helping move things forward. They're encouraging Arch to move quickly, and the team is currently waiting on next steps from Arch. There had been some confusion among other VCs about human tolerance which Marco and his team have since corrected; that previously slowed momentum but it is now picking up.
Other: Marco is meeting with the Lux team and plans to use the same fundraising packet. The company is likely receiving another ~$2M SBIR grant. Miles to make outreach to Polaris.